A phase 1/2 study of RP2 for the treatment of patients with liver metastases from various cancer types
Latest Information Update: 09 Jun 2021
At a glance
- Drugs RP 2 (Primary)
- Indications Liver metastases
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2021 New trial record
- 03 Jun 2021 According to a Replimune media release, the company is planning to expand this study to provide further signal confirmation for the treatment of patients with liver metastases from various cancer types.